- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
… I am a woman surviving it. Who calls into work sick because of eczema? That’s what I’m sure people thought when I was consistently missing work due to lack of sleep, broken and bleeding skin, and sometimes just feeling too emotionally unstable to hold it together in the office. I was doing my best […]
Understanding AD’s impact to improve your quality of life People living with atopic dermatitis (AD), the most common and chronic form of eczema, know first-hand the burden AD has on both individuals and families. The impacts reach far beyond the serious effects of the disease symptoms such as itch, pain, and inflammation –they also include […]
Eczema affects more than 30 million people in the United States. The most common and chronic form of eczema is known as atopic dermatitis (AD). There is currently no cure for eczema or AD. To help raise awareness about the serious impact AD has on individuals and families, the National Eczema Association (NEA) has joined […]
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
May 20, 2016 – Atopic dermatitis (AD) is associated with chronic itch, allergic disease and sleep disturbance, all of which might increase the risk of attention deficit (hyperactivity) disorder (ADD/ADHD).
May 2, 2016 – In the study, the research team, comprised of veterinary dermatologists, microbiologists, pathologists, and primary scientists, tracked the bacterial populations, or “microbiomes,” on dogs’ skin, and key properties of the skin’s barrier function during an occurrence of AD, and again after standard treatment with antibiotics.
April 21, 2016 – United States adults with AD have significantly impaired sleep and fatigue affecting IADLs (instrumental activity of daily living), and sleep disturbances may be under-diagnosed in this population.
April 5, 2016 – We’re one step closer to a new treatment for moderate to severe atopic dermatitis! Dupilimab, the first biologic therapy for AD, has shown in recent clinical trials to significantly clear skin and reduce itch.
March 30, 2016 – Although psoriasis was once at the forefront of therapeutic advancements in dermatology, atopic dermatitis (AD) is now taking center stage with several new treatments in the pipeline.